During these atypical times of COVID-19 Pandemic Crisis, Deurali-Janta is the first National Pharmaceutical Company to attain manufacturing License for FAVIPIRAVIR 200 mg Tablet (FAVIR 200). The drug is the recommended therapy in many countries for mild to moderate cases of COVID-19. FAVIPIRAVIR is the part of COVID-19 treatment protocol approved by NMC (Nepal Medical Council). In the history of Nepal, Deurali-Janta Pharmaceuticals is the first and only company to conduct phase III clinical trial of medicinal product (Favipiravir) in collaboration of NHRS and MoH of Nepal.
Around September 2020, the Department of Drug Administration (DDA) of Nepal approved Favipiravir manufactured by Nepalese-based company- Deurali-Janta Pharmaceuticals Pvt. Ltd., indicated for novel or re-emerging influenza virus infections, and as investigational use for novel coronavirus SARS-CoV-2 infection. Thereafter, Deurali-Janta in collaboration with National Health Research Council (NHRC) begun Nepal’s first ever phase 3 clinical trial of FAVIR 200.